227 related articles for article (PubMed ID: 15466002)
1. Evidence-based promotion.
Mattes JA
Am J Psychiatry; 2004 Oct; 161(10):1928; author reply 1929. PubMed ID: 15466002
[No Abstract] [Full Text] [Related]
2. 'Biosimilar' drugs poised to penetrate market.
Ledford H
Nature; 2010 Nov; 468(7320):18-9. PubMed ID: 21048737
[No Abstract] [Full Text] [Related]
3. Avoiding legal and ethical pitfalls of industry-sponsored research: the co-existence of research, scholarship, and marketing in the pharmaceutical industry.
Dorfman HL; Reig LP
Food Drug Law J; 2004; 59(4):595-615. PubMed ID: 15880876
[No Abstract] [Full Text] [Related]
4. Countering delays in introduction of generic drugs.
Lancet; 2002 Jan; 359(9302):181. PubMed ID: 11812545
[No Abstract] [Full Text] [Related]
5. Drug marketing exclusivity under United States and European Union law.
Junod V
Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347
[No Abstract] [Full Text] [Related]
6. Generic drugs: the stalling game.
Consum Rep; 2001 Jul; 66(7):36-40. PubMed ID: 11725791
[TBL] [Abstract][Full Text] [Related]
7. Strategies that delay or prevent the timely availability of affordable generic drugs in the United States.
Jones GH; Carrier MA; Silver RT; Kantarjian H
Blood; 2016 Mar; 127(11):1398-402. PubMed ID: 26817958
[TBL] [Abstract][Full Text] [Related]
8. Drugs, money, and power: the Canadian drug shortage.
Kaposy C
J Bioeth Inq; 2014 Mar; 11(1):85-9. PubMed ID: 24357073
[TBL] [Abstract][Full Text] [Related]
9. Biotech industry struggles with generics approval.
Knight J
Nature; 2004 Jun; 429(6992):588. PubMed ID: 15190316
[No Abstract] [Full Text] [Related]
10. Using a drug-safety tool to prevent competition.
Sarpatwari A; Avorn J; Kesselheim AS
N Engl J Med; 2014 Apr; 370(16):1476-8. PubMed ID: 24738666
[No Abstract] [Full Text] [Related]
11. Policy on 180-day marketing exclusivity for drugs marketed under abbreviated new drug applications; clarification--FDA. Clarification.
Fed Regist; 1997 Nov; 62(229):63268-9. PubMed ID: 10177950
[TBL] [Abstract][Full Text] [Related]
12. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
Dinh TQ
Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
[No Abstract] [Full Text] [Related]
13. America's other drug problem: how the drug industry distorts medicine and politics.
Relman AS; Angell M
New Repub; 2002 Dec; 227(25):27-41. PubMed ID: 12561803
[No Abstract] [Full Text] [Related]
14. Sword or shield? An overview and competitive analysis of the marketing of "authorized generics".
Zain S
Food Drug Law J; 2007; 62(4):739-77. PubMed ID: 18557229
[No Abstract] [Full Text] [Related]
15. Medicine. Shortages of cancer drugs put patients, trials at risk.
Kaiser J
Science; 2011 Apr; 332(6029):523. PubMed ID: 21527686
[No Abstract] [Full Text] [Related]
16. Congress works to permit 'biosimilar' drugs very soon.
Carroll J
Manag Care; 2009 Apr; 18(4):7-8. PubMed ID: 19472559
[No Abstract] [Full Text] [Related]
17. Path to approval proves rocky for copycat biodrugs.
Wadman M
Nature; 2005 Nov; 438(7065):154-5. PubMed ID: 16281004
[No Abstract] [Full Text] [Related]
18. [European drug policy: welcomed modernization but shortage of political proposals concerning industry and research].
Alván G
Lakartidningen; 2003 Oct; 100(44):3541-2. PubMed ID: 14651017
[No Abstract] [Full Text] [Related]
19. Therapeutic-class wars--drug promotion in a competitive marketplace.
Kessler DA; Rose JL; Temple RJ; Schapiro R; Griffin JP
N Engl J Med; 1994 Nov; 331(20):1350-3. PubMed ID: 7935706
[No Abstract] [Full Text] [Related]
20. Branded drug reformulation: the next brand vs. generic antitrust battleground.
Amoresano GV
Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032
[No Abstract] [Full Text] [Related]
[Next] [New Search]